Assessment of response of ivermectin on virological clearance in COVID 19: single centre, open labelled, randomised controlled trial

not applicable0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients admitted with COVID 19 , positive report, or are detected as positive after admission
•2. Present within 5 days of symptom onset
•3.The patient must be between the ages >5 years and 15 Kg, until 65 years of age
•4.Women in child bearing age(14-50 years) within 14 days of LMP only
•5.Mild-moderate symptoms at presentation as per Ministry of Family welfare, Government of India definitions

•1. Known history of ivermectin allergy
•2. Hypersensitivity to any component of ivermectin
•3. Refusal of consent (Appendix 5 and 6).
•4. Co-morbidities e.g. Acute or chronic renal disease , History of coronary disease , pregnancy, History of cerebrovascular disease and malignancy
•5. Current use of CYP 3A4 or P-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. Concomitant use of critical CYP3A4 substrate drugs such as warfarin.
•6.Prior use of ivermectin in last 15 days

发起方